Philippe Halfon

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Durant, Philippe Clevenbergh, Philippe Halfon et al. · The Lancet · 1999 · 761 citations

Health Sciences, Treatment And Prevention, Human Retrovirus +11

CpG Methylation Controls Reactivation of HIV from Latency

Jana Blažková, Kateřina Trejbalová, Françoise Gondois‐Rey et al. · PLoS Pathogens · 2009 · 324 citations · Full text

CMV drives clonal expansion of NKG2C ⁺ NK cells expressing self‐specific KIRs in chronic hepatitis patients

Vivien Béziat, Olav Dalgård, Tarik Asselah et al. · European Journal of Immunology · 2011 · 270 citations

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Thierry Poynard, Philippe Halfon, Laurent Castéra et al. · Clinical Chemistry · 2007 · 238 citations

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Durant, Philippe Clevenbergh, R. Garraffo et al. · AIDS · 2000 · 223 citations